Back

Establishment of an in vivo murine model of immune checkPoint inhibitors cardiotoxicity: emerging role of vascular permeability in pembrolizumab-induced cardiotoxicity.

27 August 2023 (12:00 - 12:10)
Organised by: Logo
Congress Presentation Part of: Cardiotoxicity of cancer therapies Cardiotoxicity of Drugs and Other Therapies ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Panagiotis Efentakis

National & Kapodistrian University of Athens, Athens (Greece)

5 More presentations in this session

Presentation thumbnail
Mitochondrial dynamics and myocardial metabolism alterations during anthracycline-cardiotoxicity
Miss A. Diaz-Guerra Priego (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Cardioprotection beyond the guidelines: the SAFE trial results
Doctor G. Barletta (Florence, IT)
Abstract Slides Video
Presentation thumbnail
Adult survivors of childhood cancer have significant levels of impaired cardiorespiratory fitness, inflammatory markers and poor quality of life outcomes
Doctor C. McCune (Belfast, GB)
Abstract Slides Video
Presentation thumbnail
Association between vitamin D receptor gene polymorphism and cardiomyopathy in response to adriamycin treatment among breast cancer patients
Miss R. Mokhtar (Cairo, EG)
Abstract Slides Video
Presentation thumbnail
Association between immune checkpoint inhibitors and heart failure hospitalizations: a population-based self-controlled case series
Professor G. Tse (Hong Kong, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiotoxicity of cancer therapies
Video

The Event

Event poster

ESC Congress 2023

27 August 2023 12:00 CET
You may be interested in
thumbnail
Congress Presentation
Combinatorial immune checkpoint blockade increases myocardial secretion of H-FABP, NT-Pro-BNP, NLRP-3, IL-1 and IL6: clinical implications in cardio-immuno-oncology
thumbnail
Congress Presentation
Immune checkpoint inhibition and cardiovascular toxicity
thumbnail
Congress Presentation
Cardiomyocyte but not endothelial expression of PD-L1 is required to protect from Immune-Checkpoint-Inhibitor-Associated Myocarditis (ICIM)

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources